Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(01): 132-135
DOI: 10.4103/ijmpo.ijmpo_57_19
Drug Review

Drug review: Fosaprepitant

Venkatraman Radhakrishnan
Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is a significant contributor to the treatment morbidity experienced by patients with cancer. With effective prophylactic anti-emetics given prior to administration of moderately or highly emetogenic chemotherapy (MEC or HEC) it is expected that 70-80% of patients will have no CINV. Fosaprepitant is an intravenous prodrug of aprepitant that acts as an anti-emetic by blocking the neurokinin (NK-1) receptor. Fosaprepitant in combination with dexamethasone and 5-HT3 antagonist like ondansetron has been shown to be effective in preventing CINV in patients receiving MEC or HEC. The current review discusses the pharmacology and clinical indications for the use of fosaprepitant. The evidence for the effectiveness of fosaprepitant in the prevention of CINV and the commonly observed adverse events with its administration is discussed in this review.

Keywords

Chemotherapy - fosaprepitant and NK1 antagonist - vomiting


Publication History

Article published online:
08 June 2021

© 2019. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Navari RM. et al. Management of chemotherapy-induced nausea and vomiting in pediatric patients. Paediatr Drugs 2017; 19: 213-22
    CrossrefPubMedGoogle Scholar
  • 2 Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA. et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2017; 35: 3240-61
    CrossrefPubMedGoogle Scholar
  • 3 Patel P, Robinson PD, Thackray J, Flank J, Holdsworth MT, Gibson P. et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. Pediatr Blood Cancer 2017; 64 DOI: 10.1002/pbc.26542.
    CrossrefPubMedGoogle Scholar
  • 4 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Antiemesis; 1 March, 2019. Available from: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. [Last accessed on 2019 Feb 10].
  • 5 Dupuis LL, Boodhan S, Sung L, Portwine C, Hain R, McCarthy P. et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 2011; 57: 191-8
    CrossrefPubMedGoogle Scholar
  • 6 Bayo J, Fonseca PJ, Hernando S, Servitja S, Calvo A, Falagan S. et al. Chemotherapy-induced nausea and vomiting: Pathophysiology and therapeutic principles. Clin Transl Oncol 2012; 14: 413-22
    CrossrefPubMedGoogle Scholar
  • 7 Rapoport BL. et al. Delayed chemotherapy-induced nausea and vomiting: Pathogenesis, incidence, and current management. Front Pharmacol 2017; 8: 19
    CrossrefPubMedGoogle Scholar
  • 8 Colon-Gonzalez F, Kraft WK. et al. Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert Opin Drug Metab Toxicol 2010; 6: 1277-86
    CrossrefPubMedGoogle Scholar
  • 9 Food and Drug Administration Labelling Information for Fosaprepitant in Adults. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207865lbl.pdf. [Last accessed on 2019 Mar 01].
  • 10 Food and Drug Administration Labelling Information for Fosaprepitant in Children. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022023s017lbl.pdf. [Last accessed on 2019 Mar 01].
  • 11 Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. et al. Aprepitant and fosaprepitant drug interactions: A systematic review. Br J Clin Pharmacol 2017; 83: 2148-62
    CrossrefPubMedGoogle Scholar
  • 12 Marbury TC, Ngo PL, Shadle CR, Jin B, Panebianco D, Caro L. et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol 2011; 51: 1712-20
    CrossrefPubMedGoogle Scholar
  • 13 Children's Oncology Group. Guideline for the Prevention of Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients. Available from: https://www.childrensoncologygroup.org/downloads/COG_SC_CINV_Guideline_Document_Sept_25_2015.pdf. [Last accessed on 2018 Sep 10].
  • 14 Weinstein C, Jordan K, Green SA, Khanani S, Beckford-Brathwaite E. et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: Results of a randomized, double-blind phase III trial. Ann Oncol 2016; 27: 172-8
    CrossrefPubMedGoogle Scholar
  • 15 Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA. et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol – EASE. J Clin Oncol 2011; 29: 1495-501
    CrossrefPubMedGoogle Scholar
  • 16 Ruhlmann CH, Christensen TB, Dohn LH, Paludan M, Rønnengart E, Halekoh U. et al. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): A multinational, randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Oncol 2016; 17: 509-18
    CrossrefPubMedGoogle Scholar
  • 17 Radhakrishnan V, Joshi A, Ramamoorthy J, Rajaraman S, Ganesan P, Ganesan TS. et al. Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: A double-blind, placebo-controlled, phase III randomized trial. Pediatr Blood Cancer 2019; 66: e27551
    CrossrefPubMedGoogle Scholar